Company intelligence / Profile preview
Walking Fish Therapeutics
South San Francisco, California, United Stateswalkingfishtx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company developed a platform to engineer B cells to function as protein factories and immune modulators. Their first program, WFX-001, was aimed at Fabry disease. The company closed down in May 2024 after a lead investor backed out of a critical Series B funding round.
- Therapeutic areas
- OtherOncologyImmunologyRare Diseases
- Modalities
- B cell therapiesengineered B cellscell therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Walking Fish Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Walking Fish Therapeutics.